EP 3741389 A1 20201125 - A CONNECTIVE TISSUE GROWTH FACTOR (CTGF) INHIBITOR FOR USE IN THE TREATMENT OF MUSCULAR DYSTROPHIES

Title (en)

A CONNECTIVE TISSUE GROWTH FACTOR (CTGF) INHIBITOR FOR USE IN THE TREATMENT OF MUSCULAR DYSTROPHIES

Title (de)

EIN BINDEGEWEBSWACHSTUMSFAKTOR INHIBITOR (CTGF) IN DER VERWENDUNG ZUR BEHANDLUNG VON MUSKELDYSTROPHIEN

Title (fr)

UN INHIBITEUR DU FACTEUR DU CROISSANCE DU TISSU CONJONCTIF (FCTC) DANS L'UTILISATION POUR LE TRAITEMENT DE DYSTROPHIES MUSCULAIRES

Publication

EP 3741389 A1 20201125 (EN)

Application

EP 20176176 A 20200522

Priority

US 201962852227 P 20190523
US 201962863143 P 20190618

Abstract (en)

The invention relates to methods and agents useful for treating muscular dystrophies (MDs), in particular, Duchenne muscular dystrophy (DMD). Methods and agents for treating various physiological and pathological features associated with muscular dystrophies are also provided.

IPC 8 full level

A61K 39/395 (2006.01); A61P 9/00 (2006.01); A61P 11/00 (2006.01); A61P 21/00 (2006.01)

CPC (source: EP US)

A61P 21/00 (2017.12 - US); C07K 16/22 (2013.01 - EP US); C12N 15/1136 (2013.01 - US); A61K 31/573 (2013.01 - US); A61K 31/713 (2013.01 - US); A61K 38/00 (2013.01 - EP); A61K 2039/545 (2013.01 - EP US); C07K 2317/21 (2013.01 - EP US); C07K 2317/24 (2013.01 - US); C07K 2317/76 (2013.01 - EP); C12N 2310/11 (2013.01 - US); C12N 2310/141 (2013.01 - US); C12N 2310/531 (2013.01 - US)

Citation (applicant)

US 201962863143 P 20190618
US 201962852227 P 20190523
US 7405274 B2 20080729 - LIN AL Y [US], et al
US 4816567 A 19890328 - CABILLY SHMUEL [US], et al
WO 9824893 A2 19980611 - ABGENIX INC [US]
WO 9634096 A1 19961031 - CELL GENESYS INC [US]
WO 9633735 A1 19961031 - CELL GENESYS INC [US]
WO 9110741 A1 19910725 - CELL GENESYS INC [US]
US 5545807 A 19960813 - SURANI AZIM M [GB], et al
US 5545806 A 19960813 - LONBERG NILS [US], et al
US 5569825 A 19961029 - LONBERG NILS [US], et al
US 5625126 A 19970429 - LONBERG NILS [US], et al
US 5633425 A 19970527 - LONBERG NILS [US], et al
US 5661016 A 19970826 - LONBERG NILS [US], et al
US 6982321 B2 20060103 - WINTER GREGORY PAUL [GB]
US 7087409 B2 20060808 - BARBAS III CARLOS F [US], et al
US 6075181 A 20000613 - KUCHERLAPATI RAJU [US], et al
US 6150584 A 20001121 - KUCHERLAPATI RAJU [US], et al
US 5408040 A 19950418 - GROTENDORST GARY R [US], et al
US 9816423 W 19980806
US 9929652 W 19991214
WO 9933878 A1 19990708 - JAPAN TOBACCO INC [JP], et al
US 9587015 B2 20170307 - IWASAKI SHOJI [JP], et al
WO 2013108869 A1 20130725 - UNIV OKAYAMA NAT UNIV CORP [JP]
US 7871617 B2 20110118 - LIN AL Y [US], et al
US 2010044549 W 20100805
US 5539082 A 19960723 - NIELSEN PETER E [DK], et al
US 2010022759 W 20100201
US 2010023397 W 20100205
US 2009061913 W 20091023
US 2009058013 W 20090923
US 2009039557 W 20090403
US 2009066863 W 20091204
US 2009033373 W 20090206
US 2009039438 W 20090403
US 2009037686 W 20090319
US 5830653 A 19981103 - FROEHLER BRIAN [US], et al
WO 9813526 A1 19980402 - OLIGOS ETC INC [US], et al
US 5013830 A 19910507 - OHTSUKA EIKO [JP], et al
US 5214135 A 19930525 - SRIVASTAVA SURESH C [US], et al
US 5525719 A 19960611 - SRIVASTAVA SARESH C [US], et al
WO 9203568 A1 19920305 - ISIS PHARMACEUTICALS INC [US]
US 5276019 A 19940104 - COHEN JACK S [US], et al
US 5264423 A 19931123 - COHEN JACK S [US], et al
US 9608140 W 19960531
US 9926189 W 19991105
US 0238618 W 20021209
US 6358741 B1 20020319 - SCHMIDT BRIAN FREDERICK [US], et al
US 6965025 B2 20051115 - GAARDE WILLIAM [US], et al
US 7462602 B2 20081209 - SCHULTZ GREGORY S [US], et al
US 2008070856 A1 20080320 - KREUTZER ROLAND [DE], et al
US 2008176964 A1 20080724 - FLEENOR DEBRA L [US], et al
US 8802839 B2 20140812 - STERNLICHT MARK D [US], et al
US 0238618 W 20021209
US 2009054973 W 20090825
US 2009054974 W 20090826
US 2009054975 W 20090826
US 2009054976 W 20090826
US 2012023620 W 20120202
US 201213364547 A 20120202
US 7056704 B2 20060606 - TUSCHL THOMAS [US], et al
US 7078196 B2 20060718 - TUSCHL THOMAS [US], et al
US 7459547 B2 20081202 - ZAMORE PHILLIP D [US], et al
US 7691995 B2 20100406 - ZAMORE PHILLIP D [US], et al
US 7691997 B2 20100406 - KHVOROVA ANASTASIA [US], et al
US 9612251 W 19960723
PANE M ET AL., NEUROMUSCUL DISORD., vol. 24, no. 3, 2014, pages 201 - 491
ANDREWS ET AL., ADOLESC HEALTH MED THER., vol. 9, 2018, pages 53 - 63
MCKIM ET AL., ARCH PHYS MED REHABIL., vol. 93, no. 7, 2012, pages 1117 - 1122
HENRICSON ET AL., MUSCLE NERVE., vol. 48, no. l, 2013, pages 55 - 67
MAYER ET AL., PEDIATR PULMONOL., vol. 50, no. 5, 2015, pages 487 - 494
FINDER ET AL., AM J RESPIR CRIT CARE MED., vol. 196, no. 4, 2017, pages 512 - 519
BARBER BJ ET AL., J PEDIATR., vol. 163, no. 4, October 2013 (2013-10-01), pages 1080 - 4
TANDON ET AL., JAM HEART ASSOC., vol. 4, no. 4, 2015, pages 3001338
SCHRAM ET AL., JAM COLL CARDIOL., vol. 61, no. 9, 2013, pages 948 - 954
RICOTTI ET AL., NEUROMUSCUL DISORD., vol. 29, no. 4, 2019, pages 261 - 268
MEIER ET AL., NEUROMUSCL DISORD., vol. 27, 2016, pages 307 - 314
MCDONALD ET AL., LANCET, vol. 391, no. 10119, 2018, pages 451 - 461
SEFERIAN ET AL., PLOS ONE, vol. 10, no. 2, 2015, pages e0113999
HOGREL JY ET AL., NEUROLOGY, vol. 86, no. 11, 2016, pages 1022 - 30
"Remington's Pharmaceutical Sciences", 2000, MACK PUBLISHING CO.
JONES TA ET AL., NATURE, vol. I-IV, 1986, pages 522 - 525
WARD ES ET AL., NATURE, vol. 341, 1989, pages 544 - 546
BESTE G ET AL., PROC NATL ACAD SCI USA., vol. 5, 1999, pages 1898 - 1903
KOSHKIN AA ET AL., TETRAHEDRON, vol. 54, 1998, pages 3607 - 3630
GHAHOUDI MA ET AL., FEBS LETT., vol. 414, 1997, pages 521 - 526
MOXLEY ET AL., NEUROLOGY, vol. 64, 2005, pages 13 - 20
HOR ET AL., J AM COLL CARDIOL., vol. 53, no. 14, 7 April 2009 (2009-04-07), pages 1204 - 1210
DIAZ-MANERA ET AL., ACTA MYOLGICA, vol. 34, 2015, pages 95 - 108
KOHLER GMILSTEIN C, NATURE, vol. 256, 1975, pages 495 - 497
RIECHMANN L ET AL., NATURE, vol. 332, 1988, pages 323 - 329
CLACKSON T ET AL., NATURE, vol. 352, 1991, pages 624 - 628
MARKS JD ET AL., J MOL BIOL, vol. 222, 1992, pages 581 - 597
LEE V ET AL., J IMMUNOL METHODS, vol. 284, no. 1-2, 2004, pages 119 - 132
JAKOBOVITS A ET AL., PROC NATL ACAD SCI USA, vol. 90, 1993, pages 6444 - 6448
MORRISON S ET AL., PROC NATL ACAD SCI USA, vol. 81, 1984, pages 6851 - 6855
HOOGENBOOM HRWINTER G, J. MOL. BIOL., vol. 227, 1992, pages 381
MARKS JD ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581
BOERNER R ET AL., J. IMMUNOL., vol. 147, no. l, 1991, pages 86 - 95
LI J ET AL., PROC. NATL. ACAD. SCI. USA, vol. 103, 2006, pages 3557 - 3562
MYZITHRAS ET AL., BIOANALYSIS, vol. 10, no. 6, 1 March 2018 (2018-03-01), pages 397 - 406
CHEMICAL ABSTRACTS, Columbus, Ohio, US; abstract no. 946415-13-0
ZAPATA G ET AL., PROTEIN ENG, vol. 8, no. 10, 1995, pages 1057 - 1062
BIRD KD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426
LIPOVSEK D., PROTEIN ENG DES SEL, vol. 24, 2010, pages 3 - 9
NORD K ET AL., NAT BIOTECHNOL., vol. 15, 1997, pages 772 - 777
AMSTUTZ P., PROTEIN ENG DES SEL., vol. 19, 2006, pages 219 - 229
SWAYZE EBHAT B: "Antisense Drug Technology Principles, Strategies, and Applications", 2008, CRC PRESS, pages: 144 - 182
SINGH SK ET AL., CHEM. COMMUN, vol. 4, 1998, pages 455 - 456
SUMMERTON JWELLER D, ANTISENSE NUCLEIC ACID DRUG DEV, vol. 7, 1997, pages 187 - 195
NIELSEN PE ET AL., SCIENCE, vol. 254, 1991, pages 1497 - 1500
HERDEWIJN P, ANTISENSE NUCLEIC ACID DRUG DEV, vol. 10, 2000, pages 297 - 310
SANGHVI Y S ET AL., NUCLEIC ACIDS RES, vol. 21, 1993, pages 3197 - 3203
STEC W ET AL., JAM CHEM SOC, vol. 106, 1984, pages 6077 - 6079
STEC W ET AL., J ORG. CHEM, vol. 50, 1985, pages 3908 - 3913
STEC W ET AL., J CHROMATOG, vol. 326, 1985, pages 263 - 280
LAPLANCHE JL ET AL., NUCL ACID RES, vol. 26, 1986, pages 251 - 60
FASMAN G D: "Practical Handbook of Biochemistry and Molecular Biology", 1989, CRC PRESS
KOTHAPALLI D ET AL., CELL GROWTH DIFFER, vol. 8, 1997, pages 61 - 68
SHIMO T ET AL., J BIOCHEM, vol. 124, 1998, pages 130 - 140
UCHIO K ET AL., WOUND REPAIR REGEN, vol. 12, 2004, pages 60 - 66
GUHA M ET AL., FASEB J, vol. 21, 2007, pages 3355 - 3368
"The Pharmacological Basis of Therapeutics", 2001
"Handbook of Pharmaceutical Additives", 2002, SYNAPSE INFORMATION RESOURCES, INC.
CONNOLLY ET AL., MUSCLE NERVE, vol. 51, no. 4, 2015, pages 522 - 532
MCDONALD ET AL., PARENT PROJECT MUSCULAR DYSTROPHY PULMONARY ENDPOINTS WORKSHOP, 14 April 2016 (2016-04-14)
BIRNKRANT ET AL., LANCET NEUROL., vol. 17, no. 4, 2018, pages 347 - 361
MAYHEW ET AL., DEV MED CHILD NEUROL., vol. 55, no. 11, 2013, pages 1038 - 45

Citation (search report)

[I] WO 2017100193 A1 20170615 - FIBROGEN INC [US]
[I] US 2014271573 A1 20140918 - BRANDAN ENRIQUE [CL], et al
[I] WO 2011056234 A1 20110512 - FIBROGEN INC [US], et al
[I] FIBROGEN: "Press Release: FibroGen Announces Promising Preliminary Data from an Open-label Phase 2 Study to Evaluate the Safety and Efficacy of FG-3019 in Individuals with Idiopathic Pulmonary Fibrosis (IPF) and Provides Program Update", INTERNET CITATION, 3 May 2012 (2012-05-03), pages 1 - 3, XP002747981, Retrieved from the Internet <URL:http://investor.fibrogen.com/phoenix.zhtml?c=253783&p=irol-newsArticle_Print&ID=1983434> [retrieved on 20151022]
[I] LUCAS R. SMITH ET AL: "Regulation of fibrosis in muscular dystrophy", MATRIX BIOLOGY, vol. 68-69, 1 August 2018 (2018-08-01), NL, pages 602 - 615, XP055738690, ISSN: 0945-053X, DOI: 10.1016/j.matbio.2018.01.014

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

DOCDB simple family (publication)

EP 3741389 A1 20201125; US 2020369759 A1 20201126; US 2022144931 A1 20220512

DOCDB simple family (application)

EP 20176176 A 20200522; US 202016880831 A 20200521; US 202217579581 A 20220119